Fullcryo Large-Scale Cryogenic Refrigeration System Supports the Accelerator Facility of the National Science and Education Infrastructure IP-SAFE Project

Recently, Fullcryo was invited to attend the on-site completion ceremony of the main installation of the accelerator system for the world’s first accelerator-based medical isotope targeted drug R&D platform (IP-SAFE), hosted by the Institute of Modern Physics, Chinese Academy of Sciences (hereinafter referred to as “IMP”).

Fullcryo provided a 4000W@4.5Klarge-scale Cryogenic Refrigeration System for the project, delivering core low-temperature cooling capacity support to the accelerator system of the national science and education infrastructure IP-SAFE project.

The main accelerator structure of the IP-SAFE project, constructed by IMP, has been successfully installed on-site in Lanzhou New Area. This milestone marks the most significant step forward in building the world’s first demonstration facility for mass production of alpha medical isotopes based on a superconducting linear accelerator, laying a solid foundation for the overall completion of the IP-SAFE project.

The full name of the IP-SAFE project is “Accelerator-Based Medical Isotope Pharmaceutical R&D Platform.” It is one of China’s major national science and education infrastructure projects under the 14th Five-Year Plan. Leveraging IMP’s technological expertise and accumulated strengths in high-current superconducting linear accelerators, high-power targets, and isotope separation, the project aims to achieve large-scale production of globally scarce medical alpha isotopes—Actinium-225 and Radium-223—addressing China’s long-standing reliance on imports for such high-end medical radionuclides.

Figure: Main Structure of the IP-SAFE Accelerator Facility

Since its official launch on July 5, 2024, the project team has adhered to the core principles of “breaking through bottlenecks, ensuring quality, and improving efficiency.” Through strong collaboration and dedicated effort, the team successfully completed the on-site installation of the main accelerator system in less than one and a half years in an efficient and orderly manner.

This phased achievement represents another important advancement by IMP in implementing the “Four Orientations” strategy, promoting the transformation of major scientific infrastructure achievements, and serving public health needs. Upon completion, the facility will significantly enhance China’s nuclear medicine diagnosis and treatment capabilities and inject new momentum into the development of the country’s biopharmaceutical industry.